35233-17-1

Basic information

• Product Name: Urolithin A 8-Methyl Ether
• Synonyms: Urolithin A 8-Methyl Ether;3-hydroxy-8-methoxy-6-benzo[c]chromenone;3-hydroxy-8-methoxy-6H-benzo[c]chromen-6-one;3-hydroxy-8-methoxy-benzo[c]chromen-6-one;3-hydroxy-8-methoxybenzo[c]chromen-6-one
• CAS NO: 35233-17-1
• Molecular Formula: C₁₄H₁₀O₄
• Molecular Weight: 242.23
• Mol File: 35233-17-1.mol
• Article Data: 21

Chemical Properties

• Melting Point: 242 °C(Solv: acetic acid (64-19-7))
• Boiling Point: 479.9±38.0 °C(Predicted)
• Appearance: /
• Density: 1.375±0.06 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Acetone (Slightly, Sonicated) DMSO (Slightly, Sonicated), Methanol (Slightly)
• PKA: 8.63±0.20(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: Urolithin A 8-Methyl Ether(CAS DataBase Reference)
• NIST Chemistry Reference: Urolithin A 8-Methyl Ether(35233-17-1)
• EPA Substance Registry System: Urolithin A 8-Methyl Ether(35233-17-1)

Safety Data

• Hazardous Substances Data: 35233-17-1(Hazardous Substances Data)

Usage

Description

Urolithin A 8-Methyl Ether is a chemical compound derived from the metabolism of Ellagitannin, a type of tannin found in various plants. It is an intermediate in the synthesis of Urolithin A (U847000), which is known for its anti-inflammatory and antioxidant properties.

Uses

Used in Pharmaceutical Applications:
Urolithin A 8-Methyl Ether is used as an intermediate in the synthesis of Urolithin A for its anti-inflammatory and antioxidant properties. These properties make it a potential candidate for the development of pharmaceuticals targeting inflammation and oxidative stress-related conditions.
Used in Antioxidant Formulations:
Urolithin A 8-Methyl Ether is used as an antioxidant in various formulations due to its ability to neutralize free radicals and protect cells from oxidative damage. This application can be found in the cosmetics, food, and supplement industries to enhance product shelf life and promote health benefits.
Used in Research and Development:
As a key intermediate in the synthesis of Urolithin A, Urolithin A 8-Methyl Ether is used in research and development for studying its potential therapeutic effects and exploring new applications in the medical and pharmaceutical fields.

Upstream product

• 22921-68-2 2-bromo-5-methoxy-benzoic acid 
• 108-46-3 recorcinol 
• 6971-51-3 3-methoxybenzyl alcohol 
• 586-38-9 3-Methoxybenzoic acid 
• 591-20-8 3-Bromophenol 
• 6626-15-9 4-Bromoresorcinol 
• 1256355-40-4 4-methoxy-2-(methoxycarbonyl)phenylboronic acid 

Downstream Products

• 430459-93-1 8-methoxy-3-(1-methyl-2-oxo-2-phenylethoxy)benzo[c]chromen-6-one 
• 430450-28-5 8-methoxy-3-(2-oxopropoxy)benzo[c]chromen-6-one 
• 670242-80-5 8-methoxy-3-(2-oxocyclohexyloxy)benzo[c]chromen-6-one 
• 862892-29-3 10-(t-butyl)-3-methoxybenzo[c]furo[3,2-g]chromen-5-one 
• 500204-97-7 3-methoxy-9-methyl-10-phenylbenzo[c]furo[3,2-g]chromen-5-one 
• 1143-70-0 urolithin B 
• 845438-83-7 3-(Benzyloxy)-8-methoxy-6H-benzo[c]chromen-6-one 
• 384799-32-0 3-((2-fluorobenzyl)oxy)-8-methoxy-6H-benzo[c]chromen-6-one 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel 6h-benzo[c]chromen-6-one derivatives as potential phosphodiesterase ii inhibitors

Urolithins (hydroxylated 6H-benzo[c]chromen-6-ones) are the main bioavailable metabolites of ellagic acid (EA), which was shown to be a cognitive enhancer in the treatment of neurodegenerative diseases. As part of this research, a series of alkoxylated 6H-benzo[c]chromen-6-one derivatives were designed and synthesized. Furthermore, their biological activities were evaluated as potential PDE2 inhibitors, and the alkoxylated 6H-benzo[c]chromen-6-one derivative 1f was found to have the optimal inhibitory potential (IC50: 3.67 ± 0.47 μM). It also exhibited comparable activity in comparison to that of BAY 60-7550 in vitro cell level studies.

Urolithin compound, preparation method, pharmaceutical composition and application

The invention belongs to the field of medicinal chemistry, and particularly relates to a urolithin compound, a preparation method, a pharmaceutical composition and application. The urolithin compound is a compound as shown in a general formula I or an optical isomer, an enantiomer, a diastereomer, a raceme or a raceme mixture of the compound, or a pharmaceutically acceptable salt of the compound. The urolithin compound provided by the invention has good PDE2 inhibitory activity, the enzymatic level IC50 reaches 3.67 [mu] M, and the urolithin compound can be used for treating central nervous system diseases and brain neurodegenerative process diseases, and can be used as an active component to prepare drugs for inhibiting PDE2 activity.

Synthesis, Characterization, Molecular Docking, and Biological Activities of Some Natural and Synthetic Urolithin Analogs

Urolithins (that is, hydroxy substituted benzo[c]chromen-6-one derivatives) are formed within the gastrointestinal tract following to the exposure to various ellagitannin rich diet, particularly involving pomegranate, nuts, and berries. Regarding the bioavailability deficiency of ellagitannins, the biological activities obtained through the extracts of these dietaries are attributed to the urolithin compounds, since they are bioavailable. Particularly, there are studies indicating the importance of ellagitannin-rich food for protective and alternative treatment of Alzheimer's Disease (AD). From this perspective, within this study, the major urolithins (that is, urolithins A and B), their methyl ether metabolites, as well as some synthetic urolithin analogs have been synthesized and screened for their biological activities in various enzyme inhibition (acetylcholinesterase, butyrylcholinesterase, monoamine oxidase B, cyclooxygenase 1, and cyclooxygenase 2) and antioxidant (DPPH radical scavenging) assay systems. The results pointed out the potential of urolithins to act as inhibitors on these receptors. Docking studies were also performed to investigate the possible interactions.